Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

Huntington Disease Clinical Trial

— SAN-09611  

Official title:

SAN-09611: Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05773196
• Other study ID #: SAN-09611
• Status: Recruiting
• Start date: March 14, 2023
• Est. completion date: February 28, 2025

Study information

• Verified date: April 2024
• Source: Sanguine Biosciences
• Contact: Andrew C Frisina, M.S.
• Phone: 9782394764
• Email: Afrisina[@]sanguinebio.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

OBJECTIVES:

The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease.

The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

Description:

STUDY DESIGN:

• This protocol is a single-center, single-cohort, bioresearch study enrolling up to 5 participants. The cohort is as follows:

o Cohort 1: Huntington's Disease (n=5)

• The study will enroll participants per the eligibility criteria.

• Participants will have 1 scheduled biospecimen collection visit(s). If the participant requires a recollection or is called for an extra sample donation, this will add additional volume and visit(s) to the collection schedule. The biospecimens collected from participants are whole blood.

• The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum).

• Confirmation of eligibility and medical record review by a member of the study staff will be completed for participants of the cohort before they are considered fully enrolled.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: February 28, 2025
• Est. primary completion date: February 28, 2025
• Gender: All
• Age group: 25 Years to 65 Years

Eligibility

Cohort 1: Huntington's Disease

Inclusion:

1. The participant is willing and able to provide written informed consent

2. The participant is willing and able to provide appropriate photo identification

3. Participants aged 25 to 65, inclusive

4. Participants have been diagnosed with Huntington's Disease

5. Patients must have numerical documentation of CAG repeats present in the Medical Record, along with a Huntington's Disease diagnosis.

6. Pre-existing evidence of CAG repeats should be in the range of 40-60 repeats *Preference (not required for enrollment): Patients to have different CAG repeats from each other but this is not essential.*

Exclusion:

1. Participants who are pregnant or are nursing

2. Participants with a known history of HIV, hepatitis, or other infectious diseases

3. Participants who have taken an investigational product in the last 30 days

4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

Related Conditions & MeSH terms

• Dementia
• Huntington Disease
• Huntington's Dementia

Intervention

Other:
• Biospecimen Collection
Cohort 1-Huntington's Disease: The target blood volume of each phlebotomy visit will be 20 mL. The minimum accepted volume (in the event of tough venipuncture attempts or difficulty obtaining the blood) will be 5 mL. The maximum amount that can be drawn in a 6-week period will be 100 mL (whole blood 6-week maximum). Sample Collection: 10 mL EDTA Vial (Box 1; Frozen) o Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped frozen (on dry ice) FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 1. 10 mL EDTA Vial (Box 2; Ambient) Whole blood will be collected into 1 x 10 ml EDTA tube (no in-home/laboratory processing), shipped ambient FedEx priority overnight (by 10:30 am) to Labcorp after each collection in box 2.

Locations

Country	Name	City	State
United States	Sanguine Biosciences, Inc.	Woburn	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Sanguine Biosciences	Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biospecimen Collection	The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease.	6 months
Secondary	Biorepository creation	The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.	6 months